RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells

This publication has 16 references indexed in Scilit:

• MDR1/P-Glycoprotein (ABCB1) as Target for RNA Interference-Mediated Reversal of Multidrug Resistance
  Current Drug Targets, 2006
• MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid
  International Journal of Cancer, 2005
• Protection of platinum–DNA adduct formation and reversal of cisplatin resistance by anti‐MRP2 hammerhead ribozymes in human cancer cells
  International Journal of Cancer, 2005
• Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP
  Molecular Therapy, 2005
• Modulation of Multidrug Resistance-Associated Protein 2 (Mrp2) and Mrp3 Expression and Function with Small Interfering RNA in Sandwich-Cultured Rat Hepatocytes
  Published by Elsevier ,2004
• Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference
  Cancer Gene Therapy, 2004
• ABC-transporters: implications on drug resistance from microorganisms to human cancers
  International Journal of Antimicrobial Agents, 2003
• Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi)
  FEBS Letters, 2003
• Kinetic characterization of ribozymes directed against the cisplatin resistance–associated ABC transporter cMOAT/MRP2/ABCC2
  Cancer Gene Therapy, 2001
• Enhanced transport of anticancer agents and leukotriene C₄ by the human canalicular multispecific organic anion transporter (cMOAT/MRP2)
  FEBS Letters, 1999